Allergic rhinitis therapeutics pipeline is likely to grow over next few years, on account of increasing air pollution and unchecked exposure of humans to chemicals and radiations, which lead to increase in the incidence of allergic rhinitis. Poor air quality, low market penetration of effective drugs, as most of the available drugs provide temporary relief, and increasing health awareness among people are few other factors expected to propel growth in the allergic rhinitis therapeutics pipeline. According to the latest data published by the American Academy of Allergy, Asthma & Immunology, around 8 percent of adults in the U.S. experience allergic rhinitis. Both males and females are equally susceptible to this disease.
Allergic rhinitis, also known as hay fever, is an allergic response to specific environmental allergens. The most common allergens which causes allergic rhinitis are pollen grains. The symptoms of allergic rhinitis commonly include running nose, coughing, watery eyes, itchy eyes, nose stiffness, headache, dry itchy skin and tiredness. Headache and tiredness are results of prolonged exposure to such allergen. Release of histamine, by the body, is the main cause of allergic rhinitis, when coming in contact with allergens such as grass and dust. The two types of allergic rhinitis include perennial and seasonal. Perennial allergic rhinitis occurs due to dust and mites, while seasonal allergic rhinitis occurs due to pollen grains. Few other factors associated with allergic rhinitis are smoking, exposure to chemicals, air pollution, hair spray, wood smoke, fumes and colognes. Allergic rhinitis is diagnosed by physical examination and certain tests including blood tests, skin prick tests and radioallergosorbent test (RAST). Allergic rhinitis is treated using antihistamines such as allegra, xyzal, zyrtec, clarinex and xyzal, decongestants, eye drops and nasal sprays, immunotherapy and sublingual immunotherapy. Preventing allergic rhinitis can be done by managing allergies to prevent the release of histamine.
Many companies are developing drugs for allergic rhinitis, which have shown promising result in clinical trials. Immunomic Therapeutics, Inc. is developing a drug by the name ASP 4070, in collaboration with Astellas Pharma, Inc. for the improvement of allergic rhinitis. ASP 4070 is being developed as a vaccine which acts as Th1 cell stimulants. It is in Phase I clinical stage of development. Hanlim Pharm. Co., Ltd. is currently developing HL151, which is in Phase II clinical trials. HL151 is a histamine H1 receptor antagonists and being developed as a small molecule. Anergis is developing AllerT for the treatment of patients suffering from allergic rhinitis. It is currently in Phase II stage of development and acts as a peptide vaccine that works as immunomodulator. Inmunotek S.L. is developing MG56 mannosylated drug candidate, which is in Phase II clinical trials, and is an immunomodulator.
Some of the companies having a pipeline of allergic rhinitis therapeutics include ROXALL Medizin GmbH, Stallergenes Greer, Eurofarma Laboratorios S.A., Merck Sharp & Dohme Corp., Astellas Pharma, Inc., Inmunotek S.L., Anergis, GlaxoSmithKline plc, Laboratorios Leti, S.L., Immunomic Therapeutics, Inc., Hanlim Pharm. Co., Ltd., ALK-Abello A/S, Accolade Pharmaceuticals, LLC